Indian companies Gland Pharma and Apollo Tyres report quarterly growth

Gland Pharma reported a 58.29 percent increase in consolidated net profit for the September quarter, reaching Rs 290.75 crore. The company's revenue from operations rose to Rs 1,833.58 crore, up from Rs 1,486.87 crore in the previous year. Growth was attributed to strong execution across businesses, including a 31 percent year-on-year increase in its CDMO business. During this quarter, the company launched four molecules in the US: Sugammadex, Erythromycin, Fluorouracil, and Atropine sulfate.

Apollo Tyres reported a 17 percent year-on-year increase in consolidated revenue for the second quarter, totaling Rs 7,968 crore. Consolidated net profit for the quarter rose 13 percent to Rs 292 crore. The company noted that higher input costs and supply chain disruptions related to geopolitical tensions in West Asia presented operational challenges. Additionally, the board appointed Ravi Kumar Shingari as Chief Financial Officer, effective November 4, 2026.